What is the rationale for administering hyoscine N‑butylbromide (HNBB) to a pregnant patient?

Hyoscine N-Butylbromide (HNBB) in Pregnancy

HNBB is administered to pregnant patients primarily to shorten the duration of labor, particularly the active phase of the first stage, by acting as a cervical spasmolytic agent that reduces smooth muscle spasm and facilitates cervical dilation. 1, 2, 3

Mechanism of Action in Labor

HNBB functions as a muscarinic antagonist (anticholinergic) that specifically targets the autonomic nerve supply to the cervix, reducing cervical spasm and promoting more efficient dilation during the active phase of labor. 4, 5

• The cervix is richly innervated by autonomic nerves that may impede cervical dilation through muscular spasm 4
• HNBB blocks muscarinic receptors in smooth muscle, producing a spasmolytic effect without significant systemic anticholinergic effects due to its quaternary ammonium structure and poor blood-brain barrier penetration 5
• After intravenous administration, HNBB is rapidly distributed into tissues, allowing for quick onset of action 4

Clinical Efficacy in Labor

Meta-analyses demonstrate that HNBB significantly reduces the duration of the active phase of labor by approximately 55-90 minutes depending on parity, with the most robust evidence supporting its use in primigravid women. 1, 2, 3

Duration of Labor Stages:

• First stage (active phase): Reduction of 57-61 minutes in primigravidas and 54-91 minutes in multigravidas 1, 2, 4
• Second stage: Modest reduction of approximately 2-6 minutes 1, 2
• Third stage: Minimal reduction of 0.7-3 minutes, primarily in multigravidas 1, 2

Dosing Protocol:

• Standard dose: Single intravenous injection of 20 mg (1 mL) administered during the active phase of labor 1, 4
• Intravenous route is preferred over intramuscular administration for labor augmentation 1

Safety Profile in Pregnancy

HNBB appears to have an acceptable safety profile when used during labor, with no documented adverse effects on the fetus or neonate in multiple randomized controlled trials. 1, 2, 3, 4

Maternal Safety:

• Most common adverse effects are mild: tachycardia and dry mouth 2
• No significant increase in cesarean section rates, postpartum hemorrhage, or instrumental delivery 1
• Approximately 75% of women receiving HNBB report mild adverse events compared to 57% with placebo 6

Fetal/Neonatal Safety:

• No significant differences in Apgar scores at 1 and 5 minutes 1, 2, 4
• No documented teratogenic effects or structural anomalies 1, 2, 3
• No adverse effects on birth weight or neonatal hemoglobin levels 4

Important Caveats and Limitations

The FDA classifies hyoscyamine sulfate (a related anticholinergic) as Pregnancy Category C, indicating that animal reproduction studies have not been conducted and the drug should only be given to pregnant women if clearly needed. 7

• Critical limitation: A recent high-quality double-blind RCT (2024) found that a single 20 mg intravenous dose of HNBB was NOT superior to placebo in preventing slow labor progress in nulliparous women at risk of prolonged labor 6
• This contradicts earlier meta-analyses and suggests that the effect may be less robust than previously thought, particularly in preventing (rather than treating) prolonged labor 6
• The drug should be used with caution in patients with autonomic neuropathy, hyperthyroidism, coronary heart disease, congestive heart failure, cardiac arrhythmias, hypertension, and renal disease 7
• HNBB may increase heart rate, so any pre-existing tachycardia should be investigated before administration 7

Clinical Application Algorithm

For pregnant women in active labor showing signs of slow progress:

1. Confirm active phase of labor (typically ≥4 cm cervical dilation with regular contractions) 4
2. Exclude contraindications: cardiac arrhythmias, significant tachycardia, hyperthyroidism, or known hypersensitivity 7
3. Administer 20 mg HNBB intravenously as a single dose 1, 4
4. Monitor for response within 30-60 minutes (median time to meaningful pain relief is approximately 37.5 minutes) 8
5. Monitor maternal heart rate and fetal heart rate continuously 2

The evidence suggests HNBB is most effective when used as treatment for established slow labor rather than as prophylaxis in women at risk of prolonged labor. 6, 3